Thursday May 16
The Motley Fool
Sanofi and Regeneron's Latest Partnership
This antibody is being tested in combination with methotrexate, a drug often used for the treatment of rheumatoid arthritis, and will be compared to Amgen Enbrel.
Some Types of Skin Cancer Linked to Lower Chances of Alzheimer's
There's some good news for people who have had certain kinds of skin cancer: A new study suggests that their odds of developing Alzheimer's disease may be significantly lower than it is for others.
Amgen, Inc. (AMGN): What's Its Next Catalyst?
Amgen, Inc. stock has been on a bit of a roller coaster lately. Shares are up 23% year to date, but 8% off the high set earlier this month before the company reported first-quarter earnings.
Amgen to Pay $11 Million Nationwide Medicaid Settlement
Attorney General Peter F. Kilmartin announced Tuesday that Rhode Island, as part of a nationwide settlement against the drug manufacturer Amgen, Inc., has resolved allegations that the company violated certain state false claims acts, by reporting inflated pricing data for its prescription drugs Aransep, Enbrel, Epogen, Neulats, Neupogen, and ... (more)
Pfizer results fall short; company trims profit forecast
Pfizer Inc reported lower-than-expected quarterly earnings and revenue, and the largest U.S. drugmaker trimmed its full-year profit outlook, sending its shares down 3 percent.
Enbrel's Asian Biosimilar Competitors
Enbrel, co-promoted by Amgen and Pfizer is one of the most successful drugs in history.
Pfizer hopes to cut losses to generics with new drugs
Pfizer Inc. CEO Ian Read said Thursday that continuing expirations of drug patents through 2015 will restrain revenue growth, but the world's largest drugmaker is trying to offset that with launches of several medicines and research to create new ones.
The Globe and Mail
Amgen first-quarter profit, revenue rise
ROB Insight is The Globe and Mail's exclusive feature led by a team of award-winning editors and writers who provide you with in-depth analysis on breaking business news and the issues that matter most.